Dataset Information

The proteomic landscape of platelets in Glanzmann thrombasthenia

ABSTRACT: Background: Glanzmann thrombasthenia (GT) is a rare, inherited platelet function disorder caused by mutations in the integrins of the fibrinogen receptor αIIbβ3. The deficiency can be quantitative (type I/II) or qualitative (type III). This causes lack of platelet aggregation and consequently these patients suffer from a moderate to severe bleeding tendency. Besides the absence or functional alteration of the integrins αIIb and β3, little is known about the proteomic landscape of platelets from people with GT. Objectives: We aim to evaluate the proteomic landscape of platelets in GT. Patient/Methods: Thirteen patients with GT from the Thrombocytopathy in the Netherlands (TiN) study and healthy controls were included in this study. Whole blood flow cytometry analysis was performed to quantify αIIbβ3 expression. GT was genetically confirmed. Platelets were isolated and prepared for liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Results: Flow cytometry and LC-MS/MS based αIIb expression correlated well and resulted in 11 type I GT and 2 type III GT patients. Analysis of the LC-MS/MS data revealed similar platelet proteome in GT vs healthy platelets, with downregulation of a few platelet specific proteins that are associated with α-granules. Upregulated proteins in GT were almost all genuine plasma proteins rather than platelet specific proteins. Conclusions: The proteomic landscape of GT platelets is overall similar as in healthy platelets, with downregulation of some platelet specific α-granule proteins.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Platelet, Platelet

DISEASE(S): Glanzmann's Thrombasthenia

SUBMITTER: Tatiana Shamorkina

LAB HEAD: Albert JR Heck

PROVIDER: PXD056734 | Pride | 2025-05-12

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	20180112_OR14_AG3_post0113_SA_Glanzmann_control01.raw	Raw
	20180112_OR14_AG3_post0113_SA_Glanzmann_control01_2.raw	Raw
	20180112_OR14_AG3_post0113_SA_Glanzmann_control01_3.raw	Raw
	20180112_OR14_AG3_post0113_SA_Glanzmann_control02.raw	Raw
	20180112_OR14_AG3_post0113_SA_Glanzmann_control02_2.raw	Raw

Items per page:

1 - 5 of 80

Similar Datasets

Project description:In sickle cell disease, ischemia-reperfusion injury and intravascular hemolysis produce endothelial dysfunction and vasculopathy characterized by reduced nitric oxide (NO) and arginine bioavailability. Recent functional studies of platelets in patients with sickle cell disease reveal a basally activated state, suggesting that pathological platelet activation may contribute to sickle cell disease vasculopathy. Studies were therefore undertaken to examine transcriptional signaling pathways in platelets that may be dysregulated in sickle cell disease. We demonstrate and validate here the feasibility of comparative platelet transcriptome studies on clinical samples from single donors, by the application of RNA amplification followed by microarray-based analysis of 54,000 probe sets. Data mining an existing microarray database, we identified 220 highly abundant genes in platelets and a subset of 72 relatively platelet-specific genes, defined by more than 10-fold increased expression compared to the median of other cell types in the database with amplified transcripts. The highly abundant platelet transcripts found in the current study included 82% or 70% of platelet abundant genes identified in two previous gene expression studies on non-amplified mRNA from pooled or apheresis samples, respectively. On comparing the platelet gene expression profiles in 18 patients with sickle cell disease in steady state to 12 African American controls, at a 3-fold cut-off and 5% false discovery rate, we identified ~100 differentially expressed genes, including multiple genes involved in arginine metabolism and redox homeostasis. Further characterization of these pathways using real time PCR and biochemical assays revealed increased arginase II expression and activity and decreased platelet polyamine levels. These studies suggest a potential pathogenic role for platelet arginase and altered arginine and polyamine metabolism in sickle cell disease and provide a novel framework for the study of disease-specific platelet biology. Experiment Overall Design: There are 18 sickle cell samples and 12 control samples from healthy African American volunteers.

Project description:Coronary artery disease (CAD) is the leading cause of human morbidity and mortality worldwide, underscoring the need to improve diagnostic strategies. Platelets play a major role, not only in the process of acute thrombosis during plaque rupture, but also in the formation of atherosclerosis itself. MicroRNAs are endogenous small non-coding RNAs that control gene expression and are expressed in a tissue and disease-specific manner. Therefore they have been proposed to be useful biomarkers. The aim of this study was to investigate whether differences in miRNA expression levels in platelets can be found (i) between patients with premature CAD and healthy controls and (ii) within healthy controls after and before aspirin and statin administration. In this case-control study we measured expression levels of platelet miRNAs using microarrays from 40 male patients with premature CAD and 40 age- and sex-matched healthy controls. Premature CAD was defined as a cardiac event before the age of 51 years. The patients were selected from the outpatient clinic of the Academic Medical Center (AMC) of Amsterdam, which is specialised in premature CAD. The control cohort was composed of 40 healthy Caucasian male volunteers, who were recruited by advertisement and who were matched with the cases for age and smoking habits. Individuals of this control cohort did not have a history of CVD, nor did they have a positive family history of CVD and they were not allowed to use any medication. Patients and controls were excluded when they suffered from diabetes. Most CAD patients use aspirin and statins as secondary prevention. The influence of these drugs on miRNA profiles is unknown. To assess the possible influence of medication on miRNA expression and to control for medication as confounding factor, we asked 27 volunteers in our control cohort to also use these drugs. We administered simvastatin 40 mg, once daily, for 6 weeks and during the last two weeks we added 100mg of acetyl salicylic acid, once daily. Blood samples including isolated platelets were collected at baseline in the absence of aspirin and statins and after six weeks of medication use. We also assessed platelet function using the Multiplate® Analyzer (Roche) in the absence of aspirin and statin use. In short, 300 µl whole blood was diluted with 300 µl 0.9% saline and stirred for 3 minutes at 37 ºC. Adenosine diphosphate (ADP) was added in a final concentration of 2.5 ?mol/L to initiate platelet aggregation. Aggregation was measured for 6 minutes and was reported in arbitrary aggregation units plotted against time. Also, the area under the aggregation curve (AUC) was measured. All samples were measured in the absence and presence of 200 ?mol/L indomethacin (20 min incubation with blood) to mimic the effect of aspirin use. We calculated the percentage reduction in AUC after incubation with indomethacin as an in vitro measure of the effect of aspirin use on whole blood platelet aggregation.

Dataset Information

The proteomic landscape of platelets in Glanzmann thrombasthenia

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets